Abstract
Ketamine is a noncompetitive N-methyl-D-aspartate antagonist with emerging evidence for use in medically refractory epilepsy. We describe the novel use of low-dose intravenous (IV) ketamine transitioning to enteral formulation in a patient with drug-resistant localization-related refractory epilepsy. We performed a National Library of Medicine (NLM) literature review using search terms “ketamine”, “low dose”, and “seizure” for similar cases, followed by an illustrative clinical case. Our NLM search engine methodology yielded 24 hits, none of which described use of low-dose ketamine for seizures. Anesthetic doses are used for status epilepticus, but we show that in a patient with postoperative worsening of his chronic seizure burden, low-dose IV ketamine can be used to avoid oversedation and intubation. We demonstrate that IV ketamine can be transitioned to oral regimen to shorten length of stay in the intensive care unit and hospital and has future CYP2B6 pharmacogenomic considerations for further dose individualization.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lopez Gonzalez FJ, Rodriguez Osorio X, Gil-Nagel Rein A, Carreno Martinez M, Serratosa Fernandez J, Villanueva Haba V, et al. Drug-resistant epilepsy: definition and treatment alternatives. Neurologia. 2015;30:439–46.
Pizzi MA, Kamireddi P, Tatum WO, Shih JJ, Jackson DA, Freeman WD. Transition from intravenous to enteral ketamine for treatment of nonconvulsive status epilepticus. J Intensive Care. 2017;5:54.
Fang Y, Wang X. Ketamine for the treatment of refractory status epilepticus. Seizure. 2015;30:14–20.
Shrestha GS, Joshi P, Chhetri S, Karn R, Acharya SP. Intravenous ketamine for treatment of super-refractory convulsive status epilepticus with septic shock: a report of two cases. Indian J Crit Care Med. 2015;19:283–5.
Synowiec AS, Singh DS, Yenugadhati V, Valeriano JP, Schramke CJ, Kelly KM. Ketamine use in the treatment of refractory status epilepticus. Epilepsy Res. 2013;105:183–8.
Yeh PS, Shen HN, Chen TY. Oral ketamine controlled refractory nonconvulsive status epilepticus in an elderly patient. Seizure. 2011;20:723–6.
Perks A, Cheema S, Mohanraj R. Anaesthesia and epilepsy. Br J Anaesth. 2012;108:562–71.
Staley K. Molecular mechanisms of epilepsy. Nat Neurosci. 2015;18:367–72.
US National Library of Medicine. Introduction to Boolean logic. https://www.nlm.nih.gov/bsd/disted/pubmedtutorial/020_350.html. Accessed Oct 2018.
US National Library of Medicine. PubMed search: ketamine AND low dose AND seizure. 2018. https://www.ncbi.nlm.nih.gov/pubmed/?term=ketamine+AND+low+dose+AND+seizure. Accessed Oct 2018.
Dinis-Oliveira RJ. Metabolism and metabolomics of ketamine: a toxicological approach. Forensic Sci Res. 2017;2:2–10.
Li Y, Jackson KA, Slon B, Hardy JR, Franco M, William L, et al. CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. Br J Clin Pharm. 2015;80:276–84.
Rosati A, De Masi S, Guerrini R. Ketamine for refractory status epilepticus: a systematic review. CNS Drugs. 2018;32:997–1009.
Krauss GL, Sperling MR. Treating patients with medically resistant epilepsy. Neurol Clin Pract. 2011;1:14–23.
US Food & Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. 2017. https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm. Accessed Oct 2018.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Borsato, G.S., Siegel, J.L., Rose, M.Q. et al. Ketamine in seizure management and future pharmacogenomic considerations. Pharmacogenomics J 20, 351–354 (2020). https://doi.org/10.1038/s41397-019-0120-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41397-019-0120-2
This article is cited by
-
Ontology-based identification and prioritization of candidate drugs for epilepsy from literature
Journal of Biomedical Semantics (2022)
-
The Double-Edged Sword of Seizures and Nonconvulsive Status Epilepticus on Aneurysmal Subarachnoid Hemorrhage Outcomes
Neurocritical Care (2022)